While the skin of most patients with atopic dermatitis (AD) is known to contain IgE-bearing cells, the contribution of the various IgE-binding structures to this phenomenon is not fully understood. To address this issue, we eluted cell-bound IgE from cryostat sections of lesional AD skin by acid treatment and performed reconstitution experiments with IgE in the absence or presence of reagents directed against the currently known IgE-binding structures. We found that incubation of acid-treated sections, with either chiIneric or serum IgE, resulted in the appearance of sizable numbers of anti-lgE-reactive cells. This cellular IgE loading could be entirely prevented by preincubation of the sections with the anti-FceRIa MoAb 15-1 but not with either antibodies against FceRII/CD23 and FcyRIIICD32 or with a-lactose. To exclude the possibility that acid treatment of tissue sections may have adversely influenced the IgE-binding capacity of IgE receptors other than FceRI, we A !though the cen tral role of all ergen-sp ecific IgE in the pathogen esis of res piratory allergy is w e ll establi sh e d , its contributi o n to th e eczematous lesions in cutan eou s atopy is sti ll a m atte r of conj ecture and d eb ate. Eviden ce supportin g this involvement com e s from the findings (i) that de nd,;tic antigen-presenting cell s (APes) in lesion a l an d , to a lesser extent, in n o nlesional skin of atopi c de mlatitis (AD) patients fi·equently exhibit surface-bound IgE Manu script received August 7, 1996; revised October 29, 1996 J [,west Dermatol108:336-342, 1997 mol ecul es (Bruynzee l-Koomen e ( ai, 1986; B arker e/ ai, 1988; Bieber e/ nl, 1989a), (ii) that Langerhans cell (LC )-indu ced allergellspecific T cell activati.on and prolife rati o n occur more e ffectively when the all e rgen is taken up via th ese celJ sUl'face-bound IgE mo lec ules (MlIdde et ai, 1990), and (iii) that eczematous reactions to aeroaBergens can b e mo st efficientl y induced via skin regio ns h arborin g IgE-bearing d e ndriti c cells (DCs) (Mudde et ai, 1990) . By rea soning that the prevention of IgE-faciUtated all ergen presentati o n co uld be an e ffectiv e m eans to stop the cas cade of p athogenetic eve nts occurrin g in AD, we and others aimed to ch ara c te rize the IgE-binding stru cture(s) on APCs in AD skin. Candidate molecules include (i) th e low-affinity recep tor for IgE (Fc ERlIlCD23), a si ngl e-c hain type-II integral m e mbran e mol ecule (Sutton and Gould , 1993) wh ose expressio n and release can be induced by interle ukin 4/interferon-), o n various cell types including LCs (Bie b e r et ai, 1989b); (ii) galectin-3, a /3-gala ctoside-binding protein (B arondes e/ ai, 1994) pro duced b y a variety of cell s including k e ratinocytes (KCs) (Wollenb e rg el ai, 1 993) , and monocytesl macro phages (Lill el ai, 1995) ; and (iii) the high-affinity recep tor for IgE (FcEIU) expressed as a tetrameric holoreceptor on mast cells and basophils (Ravetch and Kin er, 1991; Sutto n and Gou ld, 1993). Ev iden ce for the partici pation of FCERIlICD23 in IgE binding to LCs in AD skin ca m e fi·om th e fi ndings (i) th at th e monoclonal antibody (MoAb) BBI0, supposedly directed aga inst FCERlIlCD23
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performed an identical series of experiments on AD skin samples that, as an exception, were essentially devoid of anti-lgE-reactive cells. Again, no IgE loading was detected when these sections were preincubated with anti-FceRIa MoAbs. J [,west Dermatol108:336-342, 1997 mol ecul es (Bruynzee l-Koomen e ( ai, 1986; B arker e/ ai, 1988; Bieber e/ nl, 1989a) , (ii) that Langerhans cell (LC )-indu ced allergellspecific T cell activati.on and prolife rati o n occur more e ffectively when the all e rgen is taken up via th ese celJ sUl'face-bound IgE mo lec ules (MlIdde et ai, 1990) , and (iii) that eczematous reactions to aeroaBergens can b e mo st efficientl y induced via skin regio ns h arborin g IgE-bearing d e ndriti c cells (DCs) (Mudde et ai, 1990) . By rea soning that the prevention of IgE-faciUtated all ergen presentati o n co uld be an e ffectiv e m eans to stop the cas cade of p athogenetic eve nts occurrin g in AD, we and others aimed to ch ara c te rize the IgE-binding stru cture(s) on APCs in AD skin. Candidate molecules include (i) th e low-affinity recep tor for IgE (Fc ERlIlCD23), a si ngl e-c hain type-II integral m e mbran e mol ecule (Sutton and Gould , 1993) wh ose expressio n and release can be induced by interle ukin 4/interferon-), o n various cell types including LCs (Bie b e r et ai, 1989b); (ii) galectin-3, a /3-gala ctoside-binding protein (B arondes e/ ai, 1994) pro duced b y a variety of cell s including k e ratinocytes (KCs) (Wollenb e rg el ai, 1 993) , and monocytesl macro phages (Lill el ai, 1995) ; and (iii) the high-affinity recep tor for IgE (FcEIU) expressed as a tetrameric holoreceptor on mast cells and basophils (Ravetch and Kin er, 1991; Sutto n and Gou ld, 1993 (Capron ef nl, 1986) , prevents the binding of IgE immun e complexes to LCs (Bruynzeel-Koomen et ai, 1988) and (ii) that epidermal DCs isol ated 5'om lesional AD skin react w ith anti-CD23 MoAbs (Woll enberg ci nl, 1996 This study was un dertaken to assess the re lative contribution of FcelUI, ga lectin-3, and FCEIU for the binding of monoelonaJ an d serum IgE to resident and passenger leukocytes in AD skin.
MATElUALS AND METHODS
Patients and Sampl e Collection Skin specimens from 26 adu lt AD patients, diagnoscd acco rdin g to the criteria of Hanifin and R.njka (1980) , wcre studicd . T he paticnts receivcd nc ithcr ora l medication nor topica l corticosteroids for at least 2 wk prior to skin samplin g. After informed co nsent \vas obtai n ed, 4-111111 punch biopsies were taken from les io n a l skin under loca l anesthesia. Contro l specime ns co nsisted of normal skin from 11 h ealth), non-atopic donors and of tonsil s removcd fi'om a patient with chroni c tonsilli tis. Serum of AD paticnts and health)' co ntrol indi vidu als was o btaincd from venous b lood s'lI1lples and kept fi'ozen at -BO°C. Serum IgE concentrations wcre determ in ed b), using th e capacit)' (CA P) IgE flu orescin e imm un oassay (FEIA) (Pharmacia-LlUJ. Uppsala , Swede n). Antibod ies and Reagcnts T he fo ll owin g MoAbs we re used as blockin g reagents: mouse anti-FcEfUCt (15-1: 10 J1.g per ml; Wang el ai , 19 92), anti -FCEIUI /C D23 (MHM6; 9-44 J1.g per ml: DAKO A/S, Glostrup . Denmark), and anti-FcyR.lI /C D32 (IV.3; 10-40 J1.g pcr ml; Medarcx, Carlsbad, CAl. a-Lactose was from Sigma-A ldrich C hem ic, Deisenhofcn, Gcrmany. Primar), antibod ies used for immun ostainin g included MoAb 1.5-1 (anti-FcElUCt; ' 1.4 J1.g pe r ml), MoAb MI-IM 6 (anti-Fc€ R II /C D23: 4.4 J1.g per ml), non labcled or biotin),lated (B lOT) mouse anti-human IgE MoAb (2-5 J1.g per 1111: So uth ern Biotechno log), Associates, Birmingham. AL), pol)'c1ona l rabbit anti-hum an IgE (1 :500 dilution; CLB. Amsterdam. The Neth erlands), mouse MoAb to hum an dendriti c ce ll s (RFD I ; 10 J1.g pe r mJ; Serotec, Oxford, U.K.), B IOT-mollSe MoAb anti-h uman mast cell c h)'mase (2 J1.g per ml: C hemicon International, Tcmecula. CAl, m OllSe MoAb anti-eosi nophi l ca tiOltic protein (EG1: 1 J1.g per 1111 ; Sera-Lab. Sussex. UK). and rabbit po lydona l anti-coagul ation facto r X lll a antibody (1 :800 dil u tion; Behring, Marburg/Lallll . Ge rman )'). Flu oresce in isothi oc)',m ate (F1TC)-labeled m o use MoAbs included anti-CD45 (l-ILe-1-FITC: 2 J1.g pcr ml; Becton Di ckinson. Mountain View , CAl, anti-HLA-DR (1 .2 J1.g per ml; Becton Dickinson), anti-CDla (OKT6-FITC: 2.5 J1.g per m l: Ortho Diagnostic System s, l"ta ritan , NJ), anti-CD3 (UCHT1-F ITC: '1 J1.g per ml; DAKO A/S) . and anti-CD19 (Leu 12-FITC; 2.5 J1.g per ml: Becton Dickinso n) .
IgE-Binding Assay After eluti o n of tissue-boun d IgE with gl),cine h),drochl oride bu ffer (0.05 M g l),cine. 0 .085 M NaCI , 0.005 M KC I. 0.01 M ethylenediam inc tetraacetic acid, pH 2.5: Ishizaka and Ishi zaka, 1974) for 30 rnin 011 ice, cryostat skill sectio n s wcre incubated e ither ove rni g ht at 4°C w ith 111 0 noclonn i chinl c ri c (hU111an COll sta n t regio n heavy ch ain Ehn o usc variab le region heavy chain / li g ht chain) IgE anti-NP (dgE: 2.1-3.6 J1.g per 1111; Scrotec) o r for 1 h at 37°C with undiluted sera fi'om AD patients with IgE concentrations from 2. 1 to 3.6 J1.g pCI' ml. In cerw in experim ents, cryostat sections were pre-exposed overni gh t :It 4°C to reagents known to inhibi t IgE binding to the various IgE reccptors (sec "Antibod ies and Reagcnts") prior to their in cubatio n with c1gE o r hum'1I1 sera . IgE binding FceRI -TI-lE CR.lTICAL IgE-I3INDING STRUCTUllE IN AD SK.IN 337 was visualized as described be low (sec " Immunostaining"). Monoclonal ch.im eric IgG2 anti-NP (2.1-3.6 J1.g pCI' m l; Serotec) or undiluted serum from non-atop ic hea lthy individuals was used as negative control.
Itnmunostainillg Slides w cre washed in Tris(hydro"'y m cth),l)aminom ethan e-b uffered sa line (PH 7.6) between in cubations . To prevent nonspecifi c prote in binding, sections werc "blocked" with 5% sheep serum /3% hlllll an AB serunl (Scrotcc/JI11tllUnO AG , Vienna , Austria) for] h at rOO I11 temperature prior to incubation with the p';mar)' antibody. Antibodies and se ra were d ilu ted with stai ning buf\-cr containing 5% (wt/vol) milk proteins an d 0.1 % polyoxyethylene sorbitan monolaureate (Tween 20: Bio-Rad).
Immul1opcroxidasc Single Staining For the detection of IgE, tissue sectio ns or EBV-tral1Sformed B cells immobilized o n Adhesion Slidcs were incubated with BlOT mouse anti-hu m an IgE MoAb fo ll owcd b)' peroxidase-co njug:lted streptav idin co mpl cxcs (StreptABComplex/ HRP; DAKO A/S) and 3-am in o~9 -eth )' 1 carba zole (Sigm a-A ldri ch C hemie) in acetate buffer (pH 5.0). For the demonstration of tissue-/cell -expressed FaR] or FceIUIICD23 . the in c ubatio n chain consisted of mouse MoAb 15-1 or Ml-IM6, of BlOT -F(ab '), shcep anti-mo use immun oglobu li n (1 :800 dilution : Amersham, Littlc Chalfo nt. UK), and finall)" of th c StreptABCompicx / HIlP staining kit. Section s were co untcrstaincd \vith hClllatoxilin (Merck) and mounted in phosphate-buffered sa lin e/glycerollMowiol (I-Iocchst, Fra nkfurt am Main , Germany). Double Immunofluoresccncc Staining Cryostat sections were incubated overn ig ht at 4°C with one of the primar), MoAbs (anti-hum an IgE. 15-1, MHM6. or EG l) , followed b)' tetramethylrhodamine isothioc),anate (TlUTC)-labclcd affinity-purified goat anti-mo use IgG (l0 J1.g per ml: Atlantic Antibodies. Stillwater, MN) for 1 h at room temperature. To in crease the detectability of tissue-bound primar), antibodies. sectio ns were exposl!d to m o use IgG l (J J1.g per ml: 4S min , room te!11perature:
Sigma-Ald,-ich C hemi c) fo ll owed b)' a second exposure to T RI TC-conj ugated goat anti-mo use IgG (10 J1.g per ml). Sections were then stain ed overn ig ht at 4°C with either (i) one of the F1TC-labeled MoAbs (sec "AJl tibodies and "-eagcnts"). (ii) rabbit anri-FX lll a antibod ies followcd b)' FITC-conjugared affinity-purified swine anti-rabbit immun oglobulin (1: 1 00 dilution: DAKO A/S), (iii) MoAb I"tFD I followed by F1TC-labcled rat an ti-mou se Ig M (10 J1.g pe r m l; South ern Biotechn o logy Associates) "nd therea ftc r b)' F1TC-labeled F(ab ' )2 goat anti-rat immun oglobu Lin (S J1.g per 1111; Jackson Im!11unoResearch Laboratories. West Grove, PAl, (iv) BlOT mouse anti-ch),mase MoAbs fo llowed by FITC-streptavidin (1: 1 00 dilu tion; Amcrsham). o r (v) rabbit anti-hum an IgE antibodies followed by FITClabel ed swine anti-rabbit immunoglobu L in (1:100 dilution; DAKO A/S). When directl), co nj ugated mOll se IgG MoAbs were used for counterstaining, the sectio ns were saturated w ith non labcled m ousc IgG 1 (1-2.5 J1.g per m l) or m ouse IgG2a MoAbs (1.2 J1.g per ml ; both from Sigma-Aldricll C hem ic) of irrelevant spec ifi city. Appropriate (non)labe led isotypematched antibodies were used as negative co ntrols. All slides we re finall ), embedded in phosphate-buffered sa lin e/gl)'cero l/ Mowiol. Quantification and Lin eagc Markcr Analysis of IgE + and FCERIa + Cells in Epidcrmis and Dcrmis Peroxidase-labe led IgE+ cells, present in fivc to ten arbitraril ), chosen fie lds (covering an area of = 0.5 111m') of the cp idcrl11is as we ll as 111id and u pper dcrnl is. were co unted "vith a scrniautol1latic image ana lyzing s),ste l1l (Vid as, Kontron Elektronik. Eching. German y) ,md d,na were expressed as cells per 111m2 (mean :t SD) . Rcsu lts obta, in ed for various experim cntal groups were compa red usin g the TukeyKramer Multiple Compariso ns Test and p values of < 0.05 were considered to be statisticall ), signifi cant. Fo r immun ofl uorescence (F IT C vers us TRITC) double-labeling studies, to determine the propo rtio n of IgE ; or Fc€IUa + ce ll s express ing a b';ven lil1 ctlge marker. we screencd fivc to seven sequentia l fields of the e pidermis or mid / upp er dermis by using an cpiflu orescence mi croscope (Nikol1. Tokyo, Japan) tit a X 400 magnifica- Table I . Lesional AD Skin (AD) but not Skin from Non-Atopic Health y Volunteers (HV) Harbors Numerous IgE-Bearing Cells"
HV AD (11 = 9) (n = 9)
Epiderm is 0 120 ± 64
Denn is 11 ± 9 437 ± 93
,I IgE f-cells were visualized by irnmllll 0pcrox-idasc staini1lg. Five co 10 arbitrarily chosen micros copic fields (covering: an arca of ""'0.5 111111 2) of rhe epidermis as well as mid and up per dennis were cOlllHcd w ith a se l11i-~HIl"Oll1nti (" image an a lyzing system . Data arc expressed as numbers per mm 1 (Illl!an ~ SO).
T H E JOUflNAL OF INVESTI GATI VE DERMATO L OGY
F i ure 1. I gE expre ss ion b y A D skin cells r e sults from serum IgE binding vi a F CER! . Se rial cryosta t sectio ns o f Ie sio na I AD skin we re stained with an ti-lgE in an indirect iml11un o pcrox ida se procedure afte r bav in g bee n subj ec ted to Tri s(bydroxymethyl) amin o l1le than c-buffercd sa lin c (a). ac id trcatm eIlt (b), acid treatm ent fo ll owed by slgE (() , acid treatment consecutivel y fo ll owed by anti-FcERJ a MoA b and slgE (d), and acid treatm ent fo ll owed by a mix ture o f reagents kn ow n to bl ock 19E-bindin g to FCEIUI /CD23, FCl'RJI /CD32, and gai<:ctin -3 and then by 51gE ( .. ). Dl ack dots del in ea te th e derm al-epidermal j unctio n . Scnlc· hnr, 30 !L1ll .
tio n. T be to tal nu m ber of cells labeled wi th each antibod y and of cells th at wcre do ubl e-stain ed was co unted and the pe rce ntages of the c ell s ex pressing both an tigens was ca lcul ated .
RESULTS
AD L e sions but Not Skin of Nonatopic Persons Harbo r La rge Numbers of IgE-Bearing D e ndritic C e lls III acco rdance w ith previ o us re po rts (Bruynzeel-Koo m e n c/ Ill, 1986; Le un g cl Il l , 1987; Barker ct Ill, 1988; Biebe r ct ai, 1989<1) , anti-l gE immuno5taining of lesio nal AD skin stain ed num e ro us cell s w ithin both th e de rmis and the e pidermis (Table I) . IgE -I-ce ll s in th e u ppe r ski n la ye rs we re la rgely de ndriti c, fr equ e ntly associated w ith the microvascul a ture, and te nd ed to fo rm clusters (Fig 1a) . In sharp co ntrast, n orm al-appea t'in g skin o f health y volun teers co n tain ed o nl y few IgE 1-cell s (Table I ) loca li zed in th e uppt! r and mid de rmi s (data no t sh own) . Immun o Au orescence do ubl e labe ling of AD sectio ns revea led th at virtu all y all IgE + cell s in the e pide rmi s an d the m aj ority of IgE + cell s in th e de rmis ex hibi t anti-CD 1 a and /o r RFD l reacti vity (Ta ble II, Experilll ellt 11) indi ca tin g th a t these cell s belong to the LC/ DC fa mil y. O th e r ' gE~' cells of th e dermis included chym ase-co ntainin g m ast ce ll s, EG I + eosinophils, and FXliia + derm al de ndrocyws (Table II , Experilll cllf 11). T he lymphocyte po pulatio n o f AD skin , which co nsis ts alm os t exclusively ofT lymph ocytes, fa il ed to ex press IgE (da ta n o t sho wn).
Masking the IgE-Bi nding Site of F cERI 0', but No t the Functional Blockade of Other IgE Receptors, Prevents
Binding of Chimeric a nd Serum IgE to AD Skin Sections III a first se ri es o f ex pe rim e n ts, we eluted ill lIit/o-bo und IgE by was hin g lesio nal AD c;·yosta t skin secti o ns wi th acid-g lyc in e buffer (Fig 1 b) and de m o nstrated that in c ubatio n of these "stripped" sectio ns with eithe r c1 gE o r ato pi c st! ru m con ta inin g a hi g h titer of IgE (slgE; 3.6 fLg pe r ml) rt!s ults in an an ti-l gE stainin g pattern th at is qu alitati ve ly and quan tita ti vely indistin g uishable fi'o m that of un trea ted skin (Figs 1 , comp are a w ith c; 2a,b) . O ur furth er o bse rvati o n that . th e propo rti o nal express io n o f vari o us lineage m arke rs (CD l a, M.oA b Rf D I-reacti ve m o ie ties, c hYll1 ast!, eosinophiJ cati o ni c pro tein , FX '"a) by IgE-bearin g cell s ill "i llo (Table II, T abl e II. h n munophcnotypic Profiles of AD Skin Cells Binding IgE Epidermj s (n = 7) Derm is (n = 7)
Epide rmis (n = 7) Dermi s (n = 7) C D!a 77 ± 12 27 ± 9 CD l a II T h e propo rtio n oflgE "1 cells expressillg a give n lin eage Il wrkcr was d etermin ed hy iml11un ofl uorescen ce do ubl e-labdin g studi es. Five to seven sequen tia l ~ic lds o f the epidermis , wd mid / u pper d en n is were scree ned by lIsin g an cpiHu o rcscencc mi cr oscopc. R.es ul ts arc: cxpressed as pcrcc lll'agcs uf IgE+ ce lls (mc~1I1 .:!: SO) hea rin g a givell marke r.
It AD cryost;It skin sections we re sllbjectcd to aci d u'catm cn t fo ll owcd by in cuba tio n with cJgE. T h e pro po rtio n o f clgE i l:c ll s ex pressing a given lill e a~c markc r W ,l S d cte rm ined as descri bed ;Jbovc. R..cs ul ts arc expressed as pen:cnta gcs o f cl gE + cc ll s (m cn ll :!: SD) bcarin g a given marker. MoAbs. ' Statisticall y significa n t (p « l.05) differences betwee n experim enta l groups 4, 5, and 6 and th e positive co ntro l e"peril1l ental gro up 3. Err"r bars, SJ). (Table II , Experil/lellt b) strongly suggests tha t the above ex perimental system is su ita ble for the ch aracte rizatio n of biologicall y releva nt IgE-bindin g structures ill IIilJo. We therefore exposed "stripped" AD skin sections to reagen ts know n to interfere w ith IgE binding to FceRJ , FceRJ IICD23, ga lectin-3, and / or FcylU IICD32 (see /\Ilateria ls afl(l Met hods) and then subjected these specimens to the IgE/anti-l gE incubation protocol. Results obtai ned showed that the anti-FcelU a MoAb 15-1 (10 /-Lg pCI' 1111) completely blocked binding of clgE (Fig 2a) 
Experil/l ellt a) corresponds to that of IgE-binding cell s ex lJi"O
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or slgE (Figs ld; 2b) to th e cell s of epidermis and dennis. In sharp contrast, the anti-Fce1UIICD23 MoAb MHM6 (9 -44 /-Lg per ml) , a-lactose (O .2-0.5M) , or th e anti-FC')'LUI/CD32 MoAb IV.3 (10-40 /-Lg per ml) neith er visibl y uor numeri call y inhibited cJgE and sl gE binding (Fig le, 2a,b) . The va li dity of these IgE-binding inh.ibi tion stu dies is furthe r substantiated by our finding that MoAb MHM6, but noc 15-1 , blocked IgE bindi,n g to FcElUI/CD23~ human EBV-transformed B cell s (Fig 3) and to nsillar B lymphocy tes (data n ot shown).
To test th e possibility that acid tre atmen t may h ave altered th e IgE-bincling ca pacity of receptors other than FceRJ, we ca rried out an identical series of inhibition experim en ts o n .lesional AD skin sections that, as an exception, di splayed no detecta ble ill " illO bound IgE and th us all o.wed us to omit the acid treatment step. As w ith the situ ation w ith AD skin sectio n s exp ressing ill ,Ji"o bound IgE, th e al1 ti-Fc€RJa MoAb, but none of th e other reagents (MHM6, a -lactose, IV.3), prevented the binding of cJgE (Fig 4a) and sIgE (Fig 411) to these specimens.
An additiona l aJ'gument for che critical importan ce of FceRJ for IgE binding to AD skin cell s ca me from the anti-FceLUa singlecolo r immuno.labeling studies on "stripp ed" AD skin sections, w hi ch rev ea led a pattern (Fig 5) closely resembling th at of anti-IgE staining of n ative AD skin sections (Fig la) . This ana logy wa s furthered by immunofluorescen ce do ubl e-l abel ing experiments sh owin g t hat the vast majority of FceH.Ja+ cell s in AD skin are LCs / DCs (Fig 6) , The few remainin g FcelUa+ cell s included virtuaLly the entire population of chym ase-co n ta ining m ast cell s, 50-60'1., of EGl '" eosinophils, and = 5";', of FX lIl a+ derm al dendrocytes (data not sh own).
D ISCUSS ION
In th e skin of AD patients, LCs, dermal dendritic cell s, mast cell s. and eosin oph il s frequently bear cell surface-bo und IgE molecules (Bruynzeel-Koom en ct ai, 1986; Le un g ('/ ai, 1987; Barker et ai, 1988; Bieber CI ai, 1989a , Tanaka (' { ai, 1995  th is study). Although these cells apparently express various types ofIgE-binding moieties, i.e. , FcelU (Bieber ct ai, 1992; Wang et ai, 1992; Gounni ct ai, 1994; Osterhoff et ai, 1994) , FceRII / CD23 (Cap ron ei 111, 1986; Bruynzeel-Koo m en et ai, 1988; Bieber et ai, 1989b; Sakam oto ct ai, 1990 ;  Buckl ey ef ai, 1992) , and ga lectin-3/EBP (Truong et ai, 1993; Wollenberg et ai, 1993; Liu et ai, 1995) , the contribution of th e individual IgE receptors to the iI, IIilJO binding of se rum IgE by AD skin cell s has not been fu ll y clarifi ed . H erein. we provide evidence that, despite the reported presence of different IgE rece ptors in AD skin, FcelU is selectively respo nsible for cellular IgE binding. This is substantiated by the fi ndin gs thilt an anti-FceIl.Ja MoAb prevented the binding of m onoclonal (Bieber and Ring, 1992 ; W ang 1'1 ai, 1992; this study) and polyclonal (tlus stu dy) serum IgE to eith er acid-treated AD skin sections (i.e., cryostat sections fr0111 which ill ";110 bound IgE was elu ted) or sections devoid of detectab le ill IIi//O bound IgE. In contrast, reagents known to prevent IgE binding to FceRII /CD23 (Au bry Cl ai, 1986) and ga lecti n-3 (Fri geri and Li u , 1992), as well as an tibodies against FcyIUIICD32, an IgE-bindin g stru cture in rodents (Takizawa et (/ /, 1992) , fai led to interfere with the bindin g of e ither of the two IgE pre paration s (this stud y) . A furthe r argumen t fo r the criti ca l a.n d l1I1.iqu e ro le of FcElU in IgE bindin g to AD skin cell s comes fi·om o ur findin g tha t the anti-FcElUa-reactive cell s in AD epidermi s and dermis disp la y a simil ar, if Dot identical, cell m o rph o logy, t issue di stri bution , and immunophenotype as the cell s bearin g IgE ill /J i /Jo and binding IgE ex /J i /Jo.
Our fil ilure to block IgE binding to AD ski n cell s with the anti-C.023 MoAb MHM6 may be su rpri sin g in view of repo rts descl·ibi n g (i) FcEfUIICD23 expression on various types of AD skin ce ll s (B ru ynzeel-Koom en et Sakamoto ct (//, 1990; Buckley et (//, 1992; WolJenberg et (//, 1996) , (ii) cytokin e (in terl e ukin 4, interferon y) -induced lip-regulati o n of FCERU/CD23 o n LCs (B ieber el (/ /, 1989b), and (iu) inhibi tio n oOgE-bindin g to APC by the "a nti-CD23-like" MoAb BB10 (Bruynzeel-Koomen ef (//, 1988). We h ave also obtain ed ev idcnce that, in both IgE + and IgElesio n:! 1 AD skill samples, the anti-CD23 M oAb MHM6 stain s a few cell s in the epidermis and dermis (R. Kluba l, unpublished o bservation) . O ur fin din g th at ac id treatment compl etely rem oves the anti-CD23 reactivity of AD ski n sections (with o r without IgE + cell s) but not that of to nsillar sections o r EBY -transform ed B cell s, suggests that FCEIUI/CD23 in AD skin is present ill its soluble rather th an in the acid-resistan t transmembrane form. case, o ur blockiJl g and reconstitu tion studi es on acid-trea ted and untreated sectio ns show tha t FcelU I/C023 docs not significantly con trib ute to c1gE or sIgE binding to les io n al AD sk in ccll s.
T he {3-ga lactosid e-binding lectin , ga lectin-3, is expressed by KCs (Wo ll enberg el ai , 1993) and mo no nu clear phagocytcs (Liu cl (//, 1. 995) and ca n bind various o li gosacc harid e-rich stru ctures, including IgE and IgE receptors (Darondcs cl tI/, 1994). R .. ecentl y, Wollenberg el (/ / (1993) repo rted that the prese n ce of KC-derived ga lectin-3 aLl ows the binding of (poorl y sial ylated) hum an IgE to LC ill lI ilro. O ur results argue agai nst a critical ro le of ga lectin-3 in the b in ding of monoclo nal o r se rum 19B to AD skin ceLI s, beca use 3nti-FcEIUa MoAb treatment completely prevented and a -lactose neithcr positively uo r ncgativel y influe nced cell ular IgE loadin g.
Data prescnted in this stud y further demon strate that thc vast nH~or i ty (> 80%) of AD skin cell s c<lpabl e of FCE lU-depcndent IgE binding belo ng to the lineage of CO l a ' an d I o r RFDl + dendritic ce ll s, w hereas mast cell s, FXllla-cxpress in g dermal dendrocytes, and EG1 + eosi nophils together accou n t for onl y 15%, of IgBbinding ce ll s ill t he dermis. Conccrnin g thesc latte r cell popu latio ns, o ur immun o flu orescen ce doub le-sta ining protocol all owed for a direct dem o n stratio n of FCERIa o n mast cell s and certain FXIIl a + derma l dendrocytes but not o n eosinophils. N evertheless. o ur re cent o bservation that anti-FcEla M oA b 15-1 treatm ent of ac id-treated AD skin sections preven ted 19B binding to EGl + dermal ceUs (R.. Kluba l, unpubl is hed observatio n) as we ll as immuno hi stologic studies by GO llnni el (/ / ( 1994) and Ta naka el (// (1995) led us believe that FCEIU is th e critica l IgE-binding stru cture also on eosino phils.
A lthou g h definitive proof is lackin g, it can be assum ed th at FCEIU , as in its role 011 peri pheral bl ood APCs (Maurer cl (/ /, 1995; M aurer e/ ai , 1996), serves as an IgE-de penden t all ergen-focusin g receptor on LCs/D C s. I f so , FceRl-bearin g LCs ma y playa criti cal ro le in the path ogen es is of AD , because th ese cell s are th e first professio nal APCs to intera ct with exogeno usly delivered all e rgen s and/or IgE-reacti ve e piderma l cell -derived autoantige ns (Valenta eL 01, 1996) . It is al so feasib le th at all ergen-induced activation o f FceRl signaling pathw ays results in the pro du cti o n and release o f m ediators by LCs th at may di sturb th e e pidermal barri er and /o r tri gger th e emi gratio n of allergen-modified LCs into the d ermis . T his m ay all ow cell-bound and/o r soluble all ergen s to enter the d erma l compartment. The latter event ma y f., vo r the degranulati o n of m ast cell s, whi ch, by the re lease of endothelial cell ac tiv atin g and ch em o ta cti c £a ctors, m ay initiate the influ x o f a varie ty o f bl oodderi ved cell s includi.ng aLl ergen-specifi c (type 2) T cell s (va n del' H eijden el ai, 1991 ; Mi.ill er el ai, 1993) , as w ell as FceRl-expressin g eosinophil s and APCs (S . Wichlas, unpublished o bservati o ns) . Parall eling th ese events, LCs/D Cs m ay process the all ergcns taken up via FceRl and present thc all ergen-del;vcd pe ptidcs to T lymphocyte s in th e ski.n and /or drainin g lymph nodes. C ontinuo us suppl y of IgE-reactiv e exoge nous and/ or end ogeno us all ergen to FceRl + resident and n ewly attracted APCs will , th erefo re, lead to a prolo nged infl ammatory tissuc reaction composed o f a T celld ep endent as we ll as a T ce ll-inde pendent compo n ent.
Foll owin g thi s reasonin g, interference with th e IgE-binding a bility and / o r fun ctio nali ty of FceRl sho uld be a pro mi sing strategy for ea rl y and e fTi cient interruption o f th e pathogenetic circuits o p erative in ato pic ti ss ue inflammatio n . 
